Burden of illness in patients with possible Lennox–Gastaut syndrome: A retrospective claims-based study
ConclusionsPatients with possible LGS have significantly higher healthcare utilization and costs than patients without epilepsy or seizures. Our results suggest that direct costs associated with LGS are substantial and highlight the need for new and effective treatments. (Source: Epilepsy and Behavior)
Source: Epilepsy and Behavior - September 19, 2018 Category: Neurology Source Type: research
Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
CONCLUSIONS: Patients with possible LGS have significantly higher healthcare utilization and costs than patients without epilepsy or seizures. Our results suggest that direct costs associated with LGS are substantial and highlight the need for new and effective treatments.
PMID: 30241056 [PubMed - as supplied by publisher] (Source: Epilepsy and Behaviour)
Source: Epilepsy and Behaviour - September 18, 2018 Category: Neurology Authors: Reaven NL, Funk SE, Montouris GD, Saurer TB, Story TJ Tags: Epilepsy Behav Source Type: research
Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update
Conclusions:
TDM provides a pragmatic approach to epilepsy care, in that bespoke dose adjustments are undertaken based on drug concentrations so as to optimize clinical outcome. For the older first-generation AEDs (carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone, and valproic acid), much data have accumulated in this regard. However, this is occurring increasingly for the new AEDs (brivaracetam, eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, piracetam, pregabalin, rufinamide, stiripentol, sulthiame, tiagabine, topiramate, vigabatrin, and...
Source: Therapeutic Drug Monitoring - September 14, 2018 Category: Drugs & Pharmacology Tags: Review Article Source Type: research
Cannabis for the Treatment of Epilepsy: an Update
AbstractPurpose of ReviewFor millennia, there has been interest in the use ofcannabis for the treatment of epilepsy. However, it is only recently that appropriately powered controlled studies have been completed. In this review, we present an update on the research investigating the use of cannabidiol (CBD), a non-psychoactive component ofcannabis, in the treatment of epilepsy.Recent FindingsWhile the anticonvulsant mechanism of action of CBD has not been entirely elucidated, we discuss the most recent data available including its low affinity for the endocannabinoid receptors and possible indirect modulation of these rece...
Source: Current Neurology and Neuroscience Reports - September 8, 2018 Category: Neuroscience Source Type: research
Cannabis for the Treatment of Epilepsy: an Update.
Abstract
PURPOSE OF REVIEW: For millennia, there has been interest in the use of cannabis for the treatment of epilepsy. However, it is only recently that appropriately powered controlled studies have been completed. In this review, we present an update on the research investigating the use of cannabidiol (CBD), a non-psychoactive component of cannabis, in the treatment of epilepsy.
RECENT FINDINGS: While the anticonvulsant mechanism of action of CBD has not been entirely elucidated, we discuss the most recent data available including its low affinity for the endocannabinoid receptors and possible ...
Source: Epilepsy Curr - September 8, 2018 Category: Neurology Authors: Gaston TE, Szaflarski JP Tags: Curr Neurol Neurosci Rep Source Type: research
Cannabis for the Treatment of Epilepsy: an Update
AbstractPurpose of ReviewFor millennia, there has been interest in the use ofcannabis for the treatment of epilepsy. However, it is only recently that appropriately powered controlled studies have been completed. In this review, we present an update on the research investigating the use of cannabidiol (CBD), a non-psychoactive component ofcannabis, in the treatment of epilepsy.Recent FindingsWhile the anticonvulsant mechanism of action of CBD has not been entirely elucidated, we discuss the most recent data available including its low affinity for the endocannabinoid receptors and possible indirect modulation of these rece...
Source: Current Neurology and Neuroscience Reports - September 8, 2018 Category: Neuroscience Source Type: research
Rufinamide efficacy and safety in children aged 1 –4 years with Lennox–Gastaut syndrome
The treatment options for Lennox –Gastaut syndrome (LGS), a pediatric epileptic syndrome, are limited, especially in younger children. Rufinamide tablets were safe and effective as an add-on treatment in Korean children and adolescents (Source: Brain and Development)
Source: Brain and Development - August 27, 2018 Category: Neurology Authors: Shin Hye Kim, Hoon-Chul Kang, Joon Soo Lee, Heung Dong Kim Tags: Original article Source Type: research
Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy
This study characterizes the impact of CYP3A4 and CYP2C19 drug interactions on CLB and NCLB serum concentrations (Cp) and concentration/dose (Cp/D) ratios in pediatric patients with epilepsy.
Methods:
This was a retrospective chart review including patients older than 1 month, who received CLB between April 2012 and March 2017. Extracted data included patient demographics, CLB daily dose, CLB and NCLB Cp, calculated CLB and NCLB Cp/Cp and Cp/D ratios, and all concomitant drugs.
Results:
The study included 995 CLB concentration sets from 302 patients (median age 7.6 years and range 0.2–40.1 years). Pharmacokinetic v...
Source: Therapeutic Drug Monitoring - July 11, 2018 Category: Drugs & Pharmacology Tags: Original Article Source Type: research
Rufinamide add-on therapy for refractory epilepsy.
CONCLUSIONS: In people with drug-resistant focal epilepsy, rufinamide when used as an add-on treatment was effective in reducing seizure frequency. However, the trials reviewed were of relatively short duration and provided no evidence for the long-term use of rufinamide. In the short term, rufinamide as an add-on was associated with several adverse events. This review focused on the use of rufinamide in drug-resistant focal epilepsy and the results cannot be generalised to add-on treatment for generalised epilepsies. Likewise, no inference can be made about the effects of rufinamide when used as monotherapy.
PMID:...
Source: Cochrane Database of Systematic Reviews - April 25, 2018 Category: General Medicine Authors: Panebianco M, Prabhakar H, Marson AG Tags: Cochrane Database Syst Rev Source Type: research
[ASAP] A Short Review on Synthetic Advances toward the Synthesis of Rufinamide, an Antiepileptic Drug
Organic Process Research& DevelopmentDOI: 10.1021/acs.oprd.7b00373 (Source: Organic Process Research and Development)
Source: Organic Process Research and Development - March 29, 2018 Category: Chemistry Authors: R. D. Padmaja, Kaushik Chanda Source Type: research
Rufinamide, an antiepileptic drug, improves cognition and increases neurogenesis in the aged gerbil hippocampal dentate gyrus via increasing expressions of IGF-1, IGF-1R and p-CREB
Publication date: Available online 14 March 2018 Source:Chemico-Biological Interactions Author(s): Bai Hui Chen, Ji Hyeon Ahn, Joon Ha Park, Minah Song, Hyunjung Kim, Tae-Kyeong Lee, Jae Chul Lee, Young-Myeong Kim, In Koo Hwang, Dae Won Kim, Choong-Hyun Lee, Bing Chun Yan, Il Jun Kang, Moo-Ho Won Rufinamide is a novel antiepileptic drug and commonly used in the treatment of Lennox-Gastaut syndrome. In the present study, we investigated effects of rufinamide on cognitive function using passive avoidance test and neurogenesis in the hippocampal dentate gyrus using Ki-67 (a marker for cell proliferation), doub...
Source: Chemico Biological Interactions - March 14, 2018 Category: Biochemistry Source Type: research
Rufinamide, an antiepileptic drug, improves cognition and increases neurogenesis in the aged gerbil hippocampal dentate gyrus via increasing expressions of IGF-1, IGF-1R and p-CREB.
Abstract
Rufinamide is a novel antiepileptic drug and commonly used in the treatment of Lennox-Gastaut syndrome. In the present study, we investigated effects of rufinamide on cognitive function using passive avoidance test and neurogenesis in the hippocampal dentate gyrus using Ki-67 (a marker for cell proliferation), doublecortin (DCX, a marker for neuroblast) and BrdU/NeuN (markers for newly generated mature neurons) immunohistochemistry in aged gerbils. Aged gerbils (24-month old) were treated with 1 mg/kg and 3 mg/kg rufinamide for 4 weeks. Treatment with 3 mg/kg rufinamide, not 1 mg/kg rufina...
Source: Chemico-Biological Interactions - March 13, 2018 Category: Molecular Biology Authors: Chen BH, Ahn JH, Park JH, Song M, Kim H, Lee TK, Lee JC, Kim YM, Hwang IK, Kim DW, Lee CH, Yan BC, Kang IJ, Won MH Tags: Chem Biol Interact Source Type: research
[Use of antiepileptic drugs during breastfeeding : What do we tell the mother?]
CONCLUSION: Phenobarbital, primidone, carbamazepine, valproate and levetiracetam are probably compatible with breastfeeding. Treatment with phenytoin, ethosuximide, clonazepam, oxcarbazepine, vigabatrin, topiramate, gabapentin, pregabalin, lamotrigine and zonisamide can be authorized during breastfeeding, provided breastfed infants are carefully monitored for side effects. Since data on the use of mesuximide, clobazam, rufinamide, felbamate, lacosamide, sultiame, perampanel and retigabine are insufficient to adequately assess the risk for breastfed infants, use in breastfeeding women is in principle not recommended and sho...
Source: Der Nervenarzt - February 27, 2018 Category: Neurology Authors: Crettenand M, Rossetti AO, Buclin T, Winterfeld U Tags: Nervenarzt Source Type: research
Advanced Continuous Flow Platform for On-Demand Pharmaceutical Manufacturing.
Abstract
As a demonstration of an alternative to the challenges faced with batch pharmaceutical manufacturing including the large production footprint and lengthy time-scale, we previously reported a refrigerator-sized continuous flow system for the on-demand production of essential medicines. Building on this technology, herein we report a second-generation, reconfigurable and 25 % smaller (by volume) continuous flow pharmaceutical manufacturing platform featuring advances in reaction and purification equipment. Consisting of two compact [0.7 (L)×0.5 (D)×1.3 m (H)] stand-alone units for synthesi...
Source: Chemistry - January 31, 2018 Category: Chemistry Authors: Zhang P, Weeranoppanant N, Thomas DA, Tahara K, Stelzer T, Russell MG, O'Mahony M, Myerson AS, Lin H, Kelly LP, Jensen KF, Jamison TF, Dai C, Cui Y, Briggs N, Beingessner RL, Adamo A Tags: Chemistry Source Type: research
Lennox-Gastaut syndrome: a comprehensive review
AbstractLennox-Gastaut syndrome (LGS) is considered an epileptic encephalopathy and is defined by a triad of multiple drug-resistant seizure types, a specific EEG pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability. The prevalence of LGS is estimated between 1 and 2% of all patients with epilepsy. The etiology of LGS is often divided into two groups: identifiable (genetic-structural-metabolic) in 65 to 75% of the patients and LGS of unknown cause in others. Lennox-Gastaut syndrome may be considered as secondary network epilepsy. The seizures in LGS are us...
Source: Neurological Sciences - November 9, 2017 Category: Neurology Source Type: research
